TME Pharma Provides Results of First Exercise of Warrants Z
479,624 Warrants Z were exercised resulting in the issuance of 599,530 new ordinary shares Outstanding 3,326,104 War…
479,624 Warrants Z were exercised resulting in the issuance of 599,530 new ordinary shares Outstanding 3,326,104 War…
The exercise of Warrants Z follows a successfully completed capital increase with preferential subscription rights throu…
Als Pionier und führender Experte im Bereich Bühnentechnik und mobile Eventsolutions kündigt Mott seine Teilnahme auf de…
Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear road…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
Die Integrated Systems Europe (ISE) 2024, die führende Messe für AV- und Systemintegrationstechnologie, fand vom 30. Ja…
€1.48 million private placement secured from a group of new investors Buyback will mark the end of TME Pharma's converti…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
Constructive meeting held with FDA provided feedback and clear guidance on key aspects of further development of NOX…
. Median overall survival surpasses 19 months and continues to improve in glioblastoma patients receiving NOX-A12 comb…